Ongoing Research
At Neuronostics we are driving the science and innovation of novel digital biomarkers. We are also working on other projects as well to improve the lives of people with neurological conditions. Find out more about these projects below.
Clinical Studies
CITADEL: The clinical utility of BioEP™ in diagnostic decision making in epilepsy
The CITADEL study is a multi-centre clinical trial exploring how BioEP can enhance the diagnostic process for epilepsy. This randomised study looks at the epilepsy diagnosis pathway in first seizure clinics and compares them with and without the use of BioEP to see if it helps clinician’s diagnose epilepsy more efficiently
Main Goal: To determine if BioEP increases the diagnostic yield of EEG.
Additional Insights: The study also examines how accurately BioEP predicts future seizures.
By improving diagnostic efficiency and reducing delays, BioEP has the potential to streamline epilepsy care and support better outcomes for patients.
PRISTINE: A prospective diagnostic belief updating study to verify the utility of BioEP™ in first seizure clinics
The PRISTINE study focuses on the utility of BioEP in assisting clinical decision-making for patients presenting at first-seizure clinics.
In this study, patients at the Royal Wolverhampton NHS Trust’s first-seizure clinic have EEGs taken, and a BioEP result is generated afterwards. Clinicians first make their diagnostic decisions based on the clinical history and standard tests, then rate their confidence in the diagnosis. After viewing the BioEP result, clinicians are asked to update their confidence ratings. This allows the study to explore how BioEP influences clinicians’ confidence in diagnosing the likelihood of future seizures, without directly affecting their initial clinical decision-making.
ECLIPSE: a prospective observational study to investigate the association between BioEP™ and seizure control during ASM titration
The ECLIPSE study is tracking adults with epilepsy over six months to explore how BioEP can help assess treatment effectiveness. When patients start or adjust their anti-seizure medication (ASM), clinicians currently rely on self-reported seizure changes to evaluate progress. This study compares those reports with BioEP results to see if BioEP can provide an early indicator of how well the medication is working. Additionally, ECLIPSE aims to determine whether BioEP could help doctors personalise treatment plans from the first EEG onwards.
OASIS: a retrospective analysis of EEG for identifying seizure susceptibility in paediatrics using computational biomarkers
The OASIS study aims to validate our set of computational biomarkers (BioEP) for assessing seizure susceptibility in children aged 2-18 years. This validation is based on retrospectively collected, routinely performed non-contributory EEGs. These EEGs include routine sleep recordings as well as 24-hour ambulatory EEGs, providing a comprehensive dataset for analysis.
Ongoing Research
Prediction of treatment response to cenobamate in drug-resistant focal epilepsy using Neuronostics’ digital biomarkers
This project aims to investigate the application of computational biomarkers of EEG in predicting how patients will respond to cenobamate, a new anti-seizure medication used to treat drug-resistant focal epilepsy.
This retrospective study uses biomarkers derived from EEGs taken from 40 patients before starting cenobamate, combined with patient metadata, to predict whether patients saw a reduction in seizure frequency at 3, 6, 9 and 12 months after starting the drug. The study also aims to evaluate the effect of this drug on EEG by looking at changes in the biomarkers before and after starting cenobamate. To achieve this, follow-up EEGs were taken at least 6 months after starting cenobamate, and the resulting biomarkers compared to those at baseline.
EEG Biomarkers for Predicting Treatment Response and Drug Resistance in Epilepsy
A key challenge in epilepsy care is the inability to reliably predict whether individuals will respond to anti-seizure medications. This project investigates whether computational features extracted from EEGs can help predict treatment response in newly diagnosed epilepsy cases. By linking EEG biomarkers to long-term clinical outcomes, the research aims to support earlier identification of patients at risk of drug-resistant epilepsy and guide more tailored treatment strategies.
EEG Biomarkers for Prognosis and Risk Stratification After Traumatic Brain Injury
Traumatic brain injury (TBI) is a significant health concern, as even milder cases can result in serious long-term outcomes such as post-traumatic epilepsy (PTE) and cognitive impairments. This project explores whether EEG-based biomarkers can be used for early identification of patients at increased risk of experiencing poor outcome, enabling more targeted monitoring and intervention strategies after a TBI.
Future research areas
At Neuronostics our mission is to revolutionise diagnosis and prognosis of neurological conditions. Our first focus has been epilepsy however, we are expanding our research into other neurological conditions as well. If you are interested in partnering with us on this research, please contact us.